Global Urinary Incontinence Treatment Drugs Market to Surpass US$ 5,427.7 Million by 2027, Says Coherent Market Insights (CMI)
Washingtoner/10099225

Trending...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).

Key Trends and Analysis:

The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.

According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.

For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.

Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.

Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400

More on Washingtoner
Key Market Takeaways:

The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Competitive Landscape:

Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400

Market Segmentation:
  • Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
    • Urge Incontinence
    • Stress Incontinence
    • Over-flow Incontinence
    • Mixed Incontinence
    • Other Type
  • Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
    • Anticholinergic/Antispasmodic Agents
    • Skeletal Muscle Relaxants
    • Antidepressants
    • Alpha Blockers
    • Topical Estrogens
    • Others
  • Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urinary Incontinence Treatment Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

More on Washingtoner
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026

Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Washingtoner
_catLbl0 _catLbl1